ACN Newswire
HONG KONG, Aug 8, 2025 – (ACN Newswire) – Everest Medicines (HKEX 1952.HK) recently announced the Taiwan Food and Drug Administration (TFDA) has approved the supplementary application for NEFECON(R). NEFECON(R) is indicated to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression…
Read More
Everest Medicines Announces Full Approval of NEFECON(R) in Taiwan
Anthony Stoval
16:20
HONG KONG, Aug 8, 2025 – (ACN Newswire) – Everest Medicines (HKEX 1952.HK) recently announced the Taiwan Food and Drug Administration (TFDA) has approved the supplementary application for NEFECON(R). NEFECON(R) is indicated to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression…
